Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in indications such as non-small-cell lung cancer (NSCLC) and bladder cancer and is…
Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate’s Biomarker Epidemiology, you…
Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate’s Biomarker Epidemiology, you…
Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malignant…
Chemotherapy has formed the backbone of oncology treatment for decades, and it continues to remain a critical cornerstone of antineoplastic drug therapy. The chemotherapy market is heavily…